AUSTRALIAN CLINICAL LABS LIMITED (ACL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ACL - AUSTRALIAN CLINICAL LABS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.01

30 Jan
2023

0.000

OPEN

$3.01

0.000

HIGH

$3.01

0

LOW

$3.01

TARGET
$3.80 26.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . SLA . CAJ . GXL . HSO . MPL . MVF . NHF . HLS . RHC . SHL . VRT . MDR . M7T . HLA . PSQ . SIL . PKS . ONT . DOC . BMT . NVL . AHX . ALC .
FNARENA'S MARKET CONSENSUS FORECASTS
ACL: 1
Title FY21
Actual
FY22
Actual
FY23
Forecast
FY24
Forecast
EPS (cps) xxx 88.6 22.4 xxx
DPS (cps) xxx 53.0 N/A xxx
EPS Growth xxx 100.0% - 74.7% xxx
DPS Growth xxx 100.0% N/A xxx
PE Ratio xxx N/A 13.4 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx 59.9% 0.0% xxx

Dividend yield today if purchased 3 years ago: 5,300.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

17.61

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 23/08 - ex-div 41c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 2019202020212022
EPS Basic xxxxxxxxx88.6
DPS All xxxxxxxxx53.0
Sales/Revenue xxxxxxxxx989.3 M
Book Value Per Share xxxxxxxxx115.8
Net Operating Cash Flow xxxxxxxxx284.1 M
Net Profit Margin xxxxxxxxx18.02 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 2019202020212022
Return on Capital Employed xxxxxxxxx113.41 %
Return on Invested Capital xxxxxxxxx50.49 %
Return on Assets xxxxxxxxx32.33 %
Return on Equity xxxxxxxxx113.41 %
Return on Total Capital xxxxxxxxx61.46 %
Free Cash Flow ex dividends xxxxxxxxx238.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Credit Suisse

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

28/10/2022

3

Neutral

$4.15

37.87%

Medlab, a business acquired in December 2021, has been yet another victim of a cyber hack in Australia, Australian Clinical Labs has announced.

Personal information of approximately 223,000 individuals has been affected, while the group's broader system has not been impacted.

Citi suggests while uncertainty lingers about the ultimate negative impact, it believes the reputation risk is likely to be contained as patients tend to use the pathology providers closest to their point-of-care.

Target $4.15. Neutral.

FORECAST
Citi forecasts a full year FY23 EPS of 22.40 cents.
Citi forecasts a full year FY24 EPS of 16.80 cents.

ACL STOCK CHART